Valuation : Nipro Corporation

Market Cap 239B 1.56B 1.34B 1.27B 1.15B 2.16B 149B 2.17B 15.08B 5.8B 75.67B 5.85B 5.72B P/E 2027 *
14.8x
P/E 2028 * 11.2x
Enterprise Value 740B 4.82B 4.15B 3.93B 3.56B 6.68B 460B 6.72B 46.69B 17.95B 234B 18.1B 17.7B EV / Sales 2027 *
1.06x
EV / Sales 2028 * 1x
Free-Float
84.43%
Yield 2027 *
2.5%
Yield 2028 * 3.13%
07-31 Nipro Corporation Receives Fda 510(K) Clearance for Elisio-Hx Dialyzer and Introduces Hds to the United States CI
07-29 Vat Holding AG agreed to acquire 100% stake in Atonarp Inc. from Nipro Corporation for CHF 110 million. CI
07-14 Jefferies Adjusts Nipro's Price Target to 1,700 Yen From 1,500 Yen, Keeps at Hold MT
05-12 Nipro Corporation Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2026 and Fiscal Year Ending March 31, 2027 CI
05-12 Nipro Corporation Announces Year-End Dividend for Fiscal Year Ended March 31, 2026, Payable on June 10, 2026; Provides Second Quarter-End and Year-End Dividend Guidance for Fiscal Year Ending March 31, 2027 CI
05-01 Jefferies Adjusts Nipro's Price Target to 1,500 Yen From 1,300 Yen, Keeps at Hold MT
03-11 Nipro Fixes Record Date for Fiscal 2026 Year-End Dividend MT
02-09 Nipro Corporation Reports Earnings Results for the Nine Months Ended December 31, 2025 CI
12-24 Nipro Corporation Announces Establishment of Wholly Owned Subsidiary in Singapore CI
11-10 Nipro Corporation Announces Dividend for the Second Quarter End of Fiscal Year Ending March 31, 2026, Payable on December 10, 2025 CI
10/06/25 Samsung Bioepis Partners With Nipro to Commercialize Biosimilars in Japan MT
09/06/25 Samsung Bioepis Co., Ltd. Enters into A Strategic Partnership with NIPRO Corporation for Commercialization of Multiple Biosimilars in Japan CI
13/05/25 Jefferies Adjusts Nipro's Price Target to 1,300 Yen from 1,400 Yen, Keeps at Hold MT
1 day-0.52%
1 week-2.14%
Current month-6.41%
1 month-10.68%
3 months-14.81%
6 months-4.58%
Current year-2.61%
1 week 1,410.5
Extreme 1410.5
1,474
1 month 1,410.5
Extreme 1410.5
1,616.5
Current year 1,401
Extreme 1401
1,760.5
1 year 1,401
Extreme 1401
1,760.5
3 years 1,041
Extreme 1041
1,760.5
5 years 987
Extreme 987
1,760.5
10 years 908
Extreme 908
1,760.5
Manager TitleAgeSince
Director of Finance/CFO 57 01/06/2025
President 58 01/06/2025
Chief Administrative Officer - -
Director TitleAgeSince
Chairman 81 26/06/2025
Director/Board Member 53 01/06/2009
Director/Board Member 58 01/06/2009
Change 5-day change 1-year change 3-year change Capi.($)
-0.52%-2.14%-8.17%+15.68% 1.56B
-1.36%-5.89%-23.76%-0.44% 176B
-0.72%-3.41%-3.26%+12.32% 116B
+0.19%-2.83%+6.30%+80.17% 61.36B
-1.92%-6.01%+7.05%+38.44% 49.42B
+0.81%-3.73%-4.81%-32.56% 48.44B
-1.75%-5.54%+8.93%-20.82% 31.33B
+0.43%-11.10% - - 28.54B
+0.58%+1.84%+36.58%-12.08% 24.37B
+0.49%-7.65%-13.30%+3.79% 21.57B
Average -0.38%-4.79%+0.62%+9.39% 55.94B
Weighted average by Cap. -0.69%-4.89%-6.03%+10.85%

Financials

2027 *2028 *
Net sales 701B 4.56B 3.93B 3.72B 3.38B 6.33B 436B 6.36B 44.23B 17.01B 222B 17.14B 16.77B 729B 4.75B 4.09B 3.87B 3.51B 6.58B 453B 6.62B 45.98B 17.68B 231B 17.82B 17.43B
Net income 15.39B 100M 86.36M 81.77M 74.11M 139M 9.58B 140M 971M 373M 4.87B 376M 368M 19.95B 130M 112M 106M 96.07M 180M 12.41B 181M 1.26B 484M 6.31B 488M 477M
Net Debt 501B 3.26B 2.81B 2.66B 2.41B 4.52B 312B 4.55B 31.6B 12.15B 159B 12.25B 11.98B 489B 3.19B 2.74B 2.6B 2.36B 4.42B 304B 4.44B 30.86B 11.87B 155B 11.96B 11.7B
Logo Nipro Corporation
Nipro Corp is a Japan-based company mainly engaged in the medical, pharmaceutical, and pharma packaging businesses. It has three segments. The Medical segment consists of the domestic business division and the international business division. The domestic business division sells medical devices related to injections and infusions, artificial organs, high-performance medicines, and dialysis. The international business division, centered on the head office, has medical device manufacturing and sales bases overseas for regional expansion, selling medical devices related to injections and infusions, artificial organs, and diabetes. The Pharmaceutical segment sells pharmaceuticals related to kit preparation containers on a contract basis from pharmaceutical companies. The Pharma Packaging segment sells medical glass products such as glass tubes and ampoules, thermos flasks, and kit preparation containers in Japan.
Employees
38,593
Date Price Change Volume
11/09/26 JP¥1,438.50 -0.52% 674,800
10/09/26 JP¥1,446.00 +1.12% 1,229,600
09/09/26 JP¥1,430.00 -2.05% 698,100
08/09/26 JP¥1,460.00 +0.24% 767,900
07/09/26 JP¥1,456.50 -0.92% 535,100
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
1,438.50JPY
Average target price
1,996.00JPY
Spread / Average Target
+38.76%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 8086 Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!